Related Experiment Video

Updated: Aug 15, 2026

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior
10:05

Rodent Brain Microinjection to Study Molecular Substrates of Motivated Behavior

Published on: September 16, 2015

Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats

Karine Guillem1, Caroline Vouillac, Marc R Azar

  • 1Laboratoire de Neuropsychobiologie des Désadaptations, Unité Mixte de Recherche 5541, Centre National de la Recherche Scientifique, Université de Bordeaux 2, 33076 Bordeaux Cedex, France.

The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|September 24, 2005
PubMed

More Related Videos

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices10:04

Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices

Published on: October 29, 2012

Related Concept Videos

Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants


Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...